Evaluation of the treatment of bilharziasis with fouadin, stibophen and anthiomaline with special reference to the apparent cure-rates and relapse-rates.
D000965:Antimony / Q000627:therapeutic use*; D001557:Benzenesulfonates; D002908:Chronic Disease; D009942:Organometallic Compounds; D012008:Recurrence; D012552:Schistosomiasis / Q000628:therapy*
D001557:Benzenesulfonates; D009942:Organometallic Compounds; C077725:Stibophen; D000965:Antimony; C004409:anthiolimine
ANTIMONY/therapeutic use; SCHISTOSOMIASIS/therapy